Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
Kala Pharmaceuticals, Inc. (KALA)
Last kala pharmaceuticals, inc. earnings: 2/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.kalarx.com
Company Research
Source: Business Wire
INVELTYSTM launched in January 2019 for the treatment of post-operative inflammation and pain following ocular surgery August 15, 2019 Prescription Drug User Fee Act (PDUFA) target action date for KPI-121 0.25% for the temporary relief of signs and symptoms of dry eye disease Topline data from STRIDE 3 trial of KPI-121 0.25% expected in 4Q19 –Conference Call and Webcast Today at 4:30 p.m. ET– WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today reported financial results for the fourth quarter and full year ended December 31, 2018. Key Highlights: Launched INVELTYSTM (loteprednol etabonate ophthalmic
Show less
Read more
Impact Snapshot
Event Time:
KALA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KALA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KALA alerts
High impacting Kala Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
KALA
News
- KALA BIO, Inc. (NASDAQ: KALA) had its price target lowered by analysts at HC Wainwright from $22.00 to $21.00. They now have a "buy" rating on the stock.MarketBeat
- KALA BIO, Inc. (NASDAQ: KALA) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $15.00 price target on the stock.MarketBeat
- KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewswire
- KALA BIO to Present at TD Cowen 44th Annual Healthcare ConferenceGlobeNewswire
- KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewswire
KALA
Earnings
- 3/29/24 - Beat
KALA
Sec Filings
- 3/29/24 - Form 424B5
- 3/29/24 - Form S-8
- 3/29/24 - Form 10-K
- KALA's page on the SEC website